September 27, 2022
The Pharmaceuticals and Medical Devices Agency (PMDA) on September 26 announced a label update for MSD’s PD-1 inhibitor Keytruda (pembrolizumab), which added new data from a global PIII study that tested the drug as an adjuvant therapy for certain melanoma...read more